EGFR inhibitor, preparation method and use thereof
Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.
1. A compound of formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof:
wherein:
ring A is
Q is selected from the group consisting of a bond, O, S, NR 7 and CR 7 R 8 ;
R is hydrogen;
X 1 , X 2 and X 3 are each independently selected from the group consisting of NR 7 and CR 8 , wherein at least one of X 1 , X 2 and X 3 is NR 7 ;
R 1 is selected from the group consisting of:
wherein the three R 6 in
are optionally the same or different substituents;
R 2 is selected from the group consisting of C 1-8 alkyl and C 3-8 cycloalkyl, wherein the C 1-8 alkyl and C 3-8 cycloalkyl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, C 1-8 alkyl, C 1-8 alkoxy, haloC 1-8 alkoxy, C 3-8 cycloalkyl and C 3-8 cycloalkoxy;
R 3 is selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, C 1-8 alkyl, C 1-8 alkoxy, C 3-8 cycloalkyl, trifluoromethyl, trifluoromethoxy, SO 2 R 9 , C(O)R 10 , C(O)OR 10 and P(O)R 11 R 12 ;
each R 4 is independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —P(O)—(CH 3 ) 2 , —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ,
wherein the C 1-8 alkyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 5-10 aryl, 5- to 10-membered heteroaryl, 5- to 7-membered carbocycle, 5- to 7-membered heterocycle, C 5-7 aryl and 5- to 7-membered heteroaryl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ;
R 6 is selected from the group consisting of hydrogen, deuterium, C 1-8 alkyl, haloC 1-8 alkyl and C(O)R 10 ;
R 7 is selected from the group consisting of C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 5-10 aryl, and 5- to 10-membered heteroaryl,
wherein the C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 5-10 aryl and 5- to 10-membered heteroaryl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ;
R 8 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ,
wherein the C 1-8 alkyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 5-10 aryl and 5- to 10-membered heteroaryl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ;
R 9 is selected from the group consisting of hydrogen, deuterium, C 1-8 alkyl, C 3-8 cycloalkyl, haloC 1-8 alkyl, phenyl and p-methylphenyl;
R 10 , R 11 and R 12 are each independently selected from the group consisting of hydrogen, deuterium, C 1-8 alkyl, C 3-8 cycloalkyl, haloC 1-8 alkyl and hydroxyC 1-8 alkyl;
m is 0, 1, 2, 3 or 4;
r is 0, 1 or 2;
and
“ ” means that the substituent R has a Z or E configuration.
2. The compound of formula (I), the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is selected from the group consisting of C 1-4 alkyl and C 3-6 cycloalkyl, wherein the C 1-4 alkyl and C 3-6 cycloalkyl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, C 1-8 alkyl, C 1-8 alkoxy, haloC 1-8 alkoxy, C 3-8 cycloalkyl and C 3-8 cycloalkoxy.
3. The compound of formula (I), the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound is a compound of formula (IA):
wherein R 2 is selected from the group consisting of methyl, difluoromethyl and trifluoromethyl; and R, X 1 , X 2 , X 3 , R 1 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , m, and r are as defined in claim 1 .
4. The compound of formula (I), the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 3 , wherein the compound is selected from the group consisting of a compound of formula (IIA1) and a compound of formula (IIA2):
wherein R 2 is selected from the group consisting of methyl, difluoromethyl and trifluoromethyl; and R, X 1 , X 2 , X 3 , R 1 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , m, and r are as defined in the claim 3 .
5. A compound selected from the group consisting of:
a compound of formula (IIIA1-1), a compound of formula (IIIA1-2), a compound of formula (IIIA1-3), a compound of formula (IIIA1-4), a compound of formula (IIIA1-5), a compound of formula (IIIA1-6), a compound of formula (IVA1-1), a compound of formula (IVA1-2), a compound of formula (IVA1-3), or a stereoisomer or a pharmaceutically acceptable salt thereof:
wherein R 2 is selected from the group consisting of methyl, difluoromethyl and trifluoromethyl;
R is hydrogen;
R 1 is selected from the group consisting of:
wherein the three R 6 in
are optionally the same or different substituents;
R 3 is selected from the group consisting of hydrogen, deuterium, halogen, cyano, nitro, C 1-8 alkyl, C 1-8 alkoxy, C 3-8 cycloalkyl, trifluoromethyl, trifluoromethoxy, SO 2 R 9 , C(O)R 10 , C(O)OR 10 and P(O)R 11 R 12 ;
each R 4 is independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxy, sulfhydrl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocycylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —P(O)—(CH 3 ) 2 , —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ,
wherein the C 1-8 alkyl, C 3[ cycloalkyl, 3- to 8-memebered heterocyclyl, C 5-10 aryl, 5- to 10-membered heteroaryl, 5- to 7-membered carbocycle, 5- to 7-membered heterocycle, C 5-7 aryl and 5- to 7-membered heteroaryl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered hetercycle, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ;
R 6 is selected from the group consisting of hydrogen, deuterium, C 1-8 alkyl, haloC 1-8 alkyl and C(O)R 10 ;
R 7 selected from the group consisiting of C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 5-10 aryl, and 5- to 10-membered heteroaryl,
wherein the C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 5-10 aryl and 5- to 10-membered heteroaryl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ;
R 8 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ,
wherein the C 1-8 alkyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 5-10 aryl and 5- to 10-membered heteroaryl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ;
R 9 is selected from the group consisting of hydrogen, deuterium, C 1-8 alkyl, C 3-8 cycloalkyl, haloC 1-8 alkyl, phenyl and p-methylphenyl;
R 10 , R 11 and R 12 are each independently selected from the group consisting of hydrogen, deuterium, C 1-8 alkyl, C 3-8 cycloalkyl, haloC 1-8 alkyl and hydroxyC 1-8 alkyl;
m is 0, 1, 2, 3 or 4;
r is 0, 1 or 2;
and means that the substituent R has a Z or E configuration.
6. The compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 5 , wherein R 3 is selected from the group consisting of hydrogen, fluorine, chlorine, methyl, ethyl, isopropyl, methoxy, ethoxy, isopropoxy, cyclopropyl, cyclobutyl, trifluoromethyl and trifluoromethoxy.
7. A compound selected from the group consisting of:
or a stereoisomer or a pharmaceutically acceptable salt thereof.
8. The compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 5 , wherein R 3 is selected from the group consisting of hydrogen, fluorine, chlorine, methyl, cyclopropyl and trifluoromethyl.
9. The compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 8 , wherein:
R 3 is selected from the group consisting of hydrogen, fluorine, chlorine, methyl, cyclopropyl and trifluoromethyl; and
R 4 is selected from the group consisting of hydrogen, deuterium, halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —P(O)(CH 3 ) 2 , —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 ;
wherein the C 1-8 alkyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, C 5-10 aryl, 5- to 10-membered heteroaryl, 5- to 7-membered carbocycle, 5- to 7-membered heterocycle, C 5-7 aryl and 5- to 7-membered heteroaryl are each optionally substituted by one or more groups selected from the group consisting of halogen, hydroxy, sulfhydryl, cyano, nitro, azido, C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, 3- to 8-membered heterocyclyloxy, 3- to 8-membered heterocyclylthio, C 5-10 aryl, C 5-10 aryloxy, C 5-10 arylthio, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryloxy, 5- to 10-membered heteroarylthio, —C 0-8 —S(O)rR 9 , —C 0-8 —O—R 10 , —C 0-8 —C(O)R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 , —C 0-8 —C(O)NR 7 R 8 , —N(R 7 )—C(O)R 10 and —N(R 7 )—C(O)OR 10 .
10. The compound of formula (IIIA1-1), the compound of formula (IIIA1-2), the compound of formula (IIIA1-3), the compound of formula (IIIA1-4), the compound of formula (IIIA1-5), the compound of formula (IVA1-1), the compound of formula (IVA1-2), the compound of formula (IVA1-3), the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 9 , wherein R 3 is selected from the group consisting of hydrogen, fluorine, chlorine and trifluoromethyl; and R 4 is selected from the group consisting of hydrogen, deuterium, hydroxy, cyano, ethenyl, ethynyl, cyclopropyl, cyclobutyl, oxetan-3-yl, N—R 6 -azetidin-3-yl, cyclopropoxy, cyclobutyloxy, phenyl, phenoxy, —C 0-8 —O—R 10 , —C 0-8 —C(O)OR 10 , —C 0-8 —O—C(O)R 10 , —C 0-8 —NR 7 R 8 and —C 0-8 —C(O)NR 7 R 8 .
11. A compound selected from the group consisting of:
or a stereoisomer or a pharmaceutically acceptable salt thereof.
12. A process for preparing the compound of formula (I), the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 1 , comprising the steps of:
wherein ring A, Q, X 1 , X 2 , X 3 , R, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , m, and r, are as defined in claim 1 .
13. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier.
14. A method of treating cancer, the method comprising administering to a subject in need thereof the pharmaceutical composition according to claim 13 .
15. The method according to claim 14 , wherein the cancer is selected from the group consisting of ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin lymphoma, gastric cancer, lung cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, melanoma and mesothelioma.
16. The method according to claim 15 , wherein the cancer is non-small cell lung cancer.
17. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 7 , and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 11 , and a pharmaceutically acceptable carrier.
19. A method of treating cancer, the method comprising administering to a subject in need thereof the pharmaceutical composition according to claim 17 .
20. The method according to claim 19 , wherein the cancer is selected from the group consisting of ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin lymphoma, gastric cancer, lung cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, melanoma and mesothelioma.
21. The method according to claim 20 , wherein the cancer is non-small cell lung cancer.
22. A method of treating cancer, the method comprising administering to a subject in need thereof the pharmaceutical composition according to claim 18 .
23. The method according to claim 22 , wherein the cancer is selected from the group consisting of ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin lymphoma, gastric cancer, lung cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, melanoma and mesothelioma.
24. The method according to claim 23 , wherein the cancer is non-small cell lung cancer.
25. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 5 , and a pharmaceutically acceptable carrier.
26. A method of treating cancer, the method comprising administering to a subject in need thereof the pharmaceutical composition according to claim 25 .
27. The method according to claim 26 , wherein the cancer is selected from the group consisting of ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin lymphoma, gastric cancer, lung cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, melanoma and mesothelioma.
28. The method according to claim 27 , wherein the cancer is non-small cell lung cancer.